ArticleAntimicrobial agents and chemotherapy2014
Rifaximin modulates the vaginal microbiome and metabolome in women affected by bacterial vaginosis.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 45 citations in OpenAlex.
- The association of Chlamydia trachomatis and Mycoplasma genitalium infection with the vaginal metabolome.Scientific reports · 2020Trial
- Improvement of abnormal vaginal flora in Ugandan women by self-testing and short use of intravaginal antimicrobials.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017Trial
- Progress in interventions for vaginal microecology.Frontiers in cellular and infection microbiology · 2026Review
- Microbial regulators of physiological and reproductive health in women of reproductive age: their local, proximal and distal regulatory roles.NPJ biofilms and microbiomes · 2025Review
- Exploring the vaginal ecosystem: insights into host-microbe interactions and microbial community dynamics.Infection and immunity · 2025Review
- Fatty acid composition in the vaginal tract of cis-gender women: canary in coal mines for reproductive health?Lipids in health and disease · 2025Review
- In Vitro Bactericidal Activity of a Neomycin-Polymyxin B-Nystatin Combination Compared to Metronidazole and Clindamycin Against the Main Bacteria Involved in Bacterial Vaginosis and Aerobic Vaginitis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Microbiota metabolites in the female reproductive system: Focused on the short-chain fatty acids.Heliyon · 2023Review
- Development of a New Biomarker Model for Predicting Preterm Birth in Cervicovaginal Fluid.Metabolites · 2022Article
- The Complex Link between the Female Genital Microbiota, Genital Infections, and Inflammation.Infection and immunity · 2021Review
- Bacterial Vaginosis: What Do We Currently Know?Frontiers in cellular and infection microbiology · 2021Review
- Article
- The Role of Fatty Acid Metabolites in Vaginal Health and Disease: Application to Candidiasis.Frontiers in microbiology · 2021Review
- Metabolic profiling of Candida clinical isolates of different species and infection sources.Scientific reports · 2020Article
- Bacterial Vaginosis: Current Diagnostic Avenues and Future Opportunities.Frontiers in cellular and infection microbiology · 2020Review
- Female Gut and Genital Tract Microbiota-Induced Crosstalk and Differential Effects of Short-Chain Fatty Acids on Immune Sequelae.Frontiers in immunology · 2020Review
- The genital tract and rectal microbiomes: their role in HIV susceptibility and prevention in women.Journal of the International AIDS Society · 2019Review
- Univariate Statistical Analysis as a Guide to ¹H-NMR Spectra Signal Assignment by Visual Inspection.Metabolites · 2019Article
- Article
- Metabolic Characterization of Supernatants Produced byFrontiers in microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial vaginosis (BV) is a common vaginal disorder characterized by the decrease of lactobacilli and overgrowth of Gardnerella vaginalis and resident anaerobic vaginal bacteria. In the present work, the effects of rifaximin vaginal tablets on vaginal microbiota and metabolome of women affected by BV were investigated by combining quantitative PCR and a metabolomic approach based on (1)H nuclear magnetic resonance. To highlight the general trends of the bacterial communities and metabolomic profiles in response to the antibiotic/placebo therapy, a multivariate statistical strategy was set up based on the trajectories traced by vaginal samples in a principal component analysis space. Our data demonstrated the efficacy of rifaximin in restoring a health-like condition in terms of both bacterial communities and metabolomic features. In particular, rifaximin treatment was significantly associated with an increase in the lactobacillus/BV-related bacteria ratio, as well as with an increase in lactic acid concentration and a decrease of a pool of metabolites typically produced by BV-related bacteria (acetic acid, succinate, short-chain fatty acids, and biogenic amines). Among the tested dosages of rifaximin (100 and 25 mg for 5 days and 100 mg for 2 days), 25 mg for 5 days was found to be the most effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.